Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT07530445

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as S…

Biliary tract carcinoma (BTC) is a highly aggressive malignancy with rising incidence worldwide. Most patients present at an advanced stage and have a dismal pr…

China40 participantsStarted 2026-03-23

Treatment: Drug: QL1706 5mg/kg, iv drip,d1,Q3W; Albumin-Bound Paclitaxel 125mg/m2, iv drip, d1、d8, Q3W; Lenvatinib 8mg, po, QD

Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as S…

All recent trials (1 shown)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as S…

All recent trials (1 shown)